TsGRM Genetiko PAO

TsGRM Genetiko PAO EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of TsGRM Genetiko PAO (GECO.ME) as of Oct 28, 2026 is 26.26 M RUB. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -9.45 M RUB — a change of -377.80% (higher).

EBITDA

26.26 MRUB

YoY

-377.80%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of TsGRM Genetiko PAO is 2024 26.26 M RUB. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of TsGRM Genetiko PAO was 2023 -9.45 M RUB. It decreases by -377.80% higher compared to the previous year.

The TsGRM Genetiko PAO EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2022
-46.98 M RUB
Jan 1, 2023
-9.45 M RUB
Jan 1, 2024
26.26 M RUB
The TsGRM Genetiko PAO EBITDA history
YEAREBITDAYoY
26.26 MRUB-377.80%
-9.45 MRUB-79.88%
-46.98 MRUB—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TsGRM Genetiko PAO Stock analysis

What does TsGRM Genetiko PAO do? TsGRM Genetiko PAO generates revenue through medical genetic services provided to doctors and patients via its four specialized laboratories. The company offers complex genetic diagnostics for hereditary diseases and reproductive disorders through its Next-Generation Sequencing (NGS) laboratory, Non-Invasive Prenatal Testing (NIPT) laboratory, Oncogenetics laboratory, and Genotyping laboratory. These services are delivered to healthcare professionals and individuals seeking genetic analysis. The firm's laboratory and production complexes form the core of its service delivery model, focusing on diagnostic solutions for medical genetics. TsGRM Genetiko PAO's primary customers are doctors who order genetic tests for their patients and patients directly seeking genetic diagnostics. The company's services include hereditary disease diagnostics and reproductive disorder assessments, which are conducted in its dedicated laboratory facilities. The firm's business model centers on providing specialized genetic testing services through its internal laboratory infrastructure without external partnerships or additional product lines. The company operates exclusively within the medical genetic services sector, delivering diagnostic solutions through its four laboratory divisions. Revenue is derived from the execution of genetic tests across all laboratory types, with no mention of additional product lines or external collaborations. The firm's structure is defined by its internal laboratory network, which serves both medical professionals and end patients. TsGRM Genetiko PAO is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TsGRM Genetiko PAO stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of TsGRM Genetiko PAO is 26.26 M RUB in 2024.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of TsGRM Genetiko PAO changed from -9.45 M RUB to 26.26 M RUB, representing a -377.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) TsGRM Genetiko PAO since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s RUB is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TsGRM Genetiko PAO historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — TsGRM Genetiko PAO

All Key Metrics — TsGRM Genetiko PAO